8-K: Sight Sciences Q3 2025: Revenue Beat, Leadership Shift

Sight Sciences reports Q3 2025 financial results, raises full-year revenue guidance, and announces key executive and board appointments.

Summary

• Reported third-quarter 2025 total revenue of $19.9 million, a 1% decrease compared to the same period in the prior year.
• Surgical Glaucoma revenue increased 6% to $19.7 million, driven by an 8% increase in ordering accounts to an all-time high of 1,197.
• Dry Eye revenue significantly decreased by 88% to $0.2 million, reflecting a strategic focus on achieving reimbursed market access for TearCare.
• Reduced total operating expenses by 11% to $25.1 million, including $2.8 million in restructuring costs associated with a workforce reduction announced in August 2025.
• Net loss improved to $8.2 million, or $0.16 per share, compared to $11.1 million, or $0.22 per share, in Q3 2024.
• Raised full-year 2025 revenue guidance to $76.0 million $78.0 million (previously $72.0 million $76.0 million).
• Reduced full-year 2025 adjusted operating expense guidance to $90 million $92 million (previously $95 million $99 million).
• Alison Bauerlein was promoted to Chief Operating Officer, and James Rodberg was appointed Chief Financial Officer, effective November 5, 2025.
• Board members Brenda Becker and Erica Rogers resigned, and the Board size was reduced from nine to seven members, effective November 4, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated improved financial performance with a reduced net loss and better-than-expected guidance for both revenue and operating expenses. Strategic executive appointments and significant reimbursement wins for key products (TearCare, OMNI) are strong positive indicators for future growth and market access. While Dry Eye revenue declined due to a strategic shift, this is framed as a necessary step for long-term reimbursed market penetration.

Positives

• Raised full-year 2025 revenue guidance to $76.0 million $78.0 million, indicating stronger expected performance.
• Reduced full-year 2025 adjusted operating expense guidance to $90 million $92 million, reflecting disciplined cost management.
• Surgical Glaucoma revenue increased by 6% year-over-year to $19.7 million.
• Surgical Glaucoma ordering accounts reached an all-time high of 1,197, up 8% from Q3 2024.
• Total operating expenses decreased by 11% to $25.1 million, contributing to a lower net loss.
• Gross margin improved to 86% in Q3 2025, up from 84% in Q3 2024.
• Net loss per share improved to $0.16 from $0.22 in the prior year.
• Significant reimbursement milestones achieved for TearCare with Novitas Solutions and First Coast Service Options establishing fee schedules covering 10.4 million Medicare lives.
• UnitedHealthcare expanded coverage for OMNI Surgical System, effective October 1, 2025, covering approximately 30 million commercial and individual exchange lives.
• Positive clinical data for TearCare (inclusion in TFOS DEWS III Global Dry Eye Guidelines) and OMNI (meta-analysis showing long-term IOP and medication reduction).
• Strong balance sheet with $92.4 million in cash and cash equivalents as of September 30, 2025.
• Strategic executive promotions of Alison Bauerlein to COO and James Rodberg to CFO are expected to accelerate growth and enhance operational focus.

Negatives

• Total revenue decreased by 1% year-over-year to $19.9 million.
• Dry Eye revenue significantly declined by 88% to $0.2 million, due to a strategic shift towards reimbursed market access, resulting in fewer SmartLids sales.
• Dry Eye gross margin decreased to 38% from 48% in the prior year.
• Cash and cash equivalents decreased to $92.4 million from $101.5 million as of June 30, 2025, with $9.1 million cash used in Q3 2025.
• Surgical Glaucoma segment's cost of goods sold increased by $0.4 million due to tariffs in Q3 2025, with an expected full-year impact of $1.0 million to $1.5 million.

Risks

• Incremental or unanticipated changes in tariff policies or rates impacting products or the medical device industry.
• Changes to reimbursement coverage, payment decisions, or reimbursement rates for products.
• Changes to product pricing or market share resulting from the evolving competitive landscape.
• Unforeseen changes in regulatory requirements.
• Disruptions to or increased costs associated with the supply chain, including as a result of having a limited number of suppliers.

Future Outlook

The company expects sustained long-term growth, particularly as a pioneer in reimbursed interventional dry eye procedures, following recent carrier-priced fee schedules for TearCare. Management is confident in maintaining momentum in both the Surgical Glaucoma and Dry Eye segments, while driving strong gross margins and disciplined expense management. Full-year 2025 revenue guidance has been raised to $76.0 million to $78.0 million, and adjusted operating expense guidance has been lowered to $90 million to $92 million, reflecting anticipated savings from workforce reductions and operational efficiencies. The company plans to continue investments in its R&D pipeline, clinical, and commercial infrastructure, and aims to expand OMNI utilization and TearCare market access.

Management Comments

• "Our robust third-quarter performance and recent progress across both our interventional dry eye and glaucoma business segments demonstrates strong consistent commercial, clinical, market access, and operational execution as we build a leading interventional eye care company." Paul Badawi, CEO
• "Our Surgical Glaucoma revenue growth underscores the clinical significance of our OMNI technology in the glaucoma treatment paradigm and the effectiveness of our team, as we simultaneously streamlined the organization and drove efficiencies to reduce operating expenses." Paul Badawi, CEO
• "In October, we achieved a transformational milestone within our Dry Eye segment, with new carrier-priced fee schedules established for TearCare. We believe we are well-positioned for sustained long-term growth as the pioneer in reimbursed interventional dry eye procedures." Paul Badawi, CEO
• "Our strengthened executive team is structured to ensure the organization continues to execute effectively on the opportunities in front of us. We are confident in our ability to maintain the momentum we are building in both segments, while driving strong gross margins and disciplined expense management." Paul Badawi, CEO
• "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category." Paul Badawi, CEO
• "I am delighted to be moving into the COO role at Sight Sciences at this critical juncture as we look to scale our business. I am excited to leverage my background in high growth medtech to help Sight Sciences achieve its fullest potential." Alison Bauerlein, COO
• "It's an exciting time at Sight Sciences given the significant patient impact we are positioned to make over the coming years by enabling our customers to treat two major obstructive ophthalmic diseases with proven procedural interventions. I look forward to supporting our growth and profitability goals, while striving to create significant value for the ophthalmic community, our patients, and our shareholders." James Rodberg, CFO
• "Erica's high-growth medtech leadership experience was invaluable as we scaled our business from early commercialization, and Brenda's decades of public service and private sector expertise helped support our execution in both glaucoma and dry eye with steadfast advice and support." Staffan Encrantz, Chairman of the Board

Industry Context

The eyecare technology industry is seeing a shift towards interventional solutions for chronic eye diseases like glaucoma and dry eye, moving beyond traditional medication management. Sight Sciences is positioning itself as a leader in this transformation with its OMNI Surgical System for glaucoma and TearCare System for dry eye. The recent reimbursement wins for TearCare (MAC fee schedules, UHC coverage for OMNI) are critical for expanding market access and adoption, aligning with the industry's push for broader coverage of innovative, minimally invasive procedures. The focus on reducing operating expenses while investing in R&D and commercial infrastructure reflects a common strategy among medtech companies to achieve profitable growth in competitive markets.

Comparison to Industry Standards

• The OMNI Surgical System is highlighted as the most comprehensive implant-free Minimally Invasive Glaucoma Surgery (MIGS) technology, indicated for use in combination cataract or standalone procedures, accessing 360 degrees of the diseased conventional outflow pathway, positioning it favorably against other MIGS devices that may have more limited indications or require implants.
• TearCare is presented as the only FDA-cleared interventional, open-eye, thermal-activated gland expression therapy designed to treat Meibomian Gland Dysfunction (MGD). The SAHARA RCT results showing TearCare's superiority over Restasis in tear break-up time improvement and durability for up to two years provide a strong clinical benchmark against a widely used pharmaceutical treatment for dry eye.
• The company's gross margin of 86% for Q3 2025, with Surgical Glaucoma at 87%, indicates a healthy margin profile, which is generally competitive within the specialized medical device sector.
• The strategic shift in the Dry Eye segment to prioritize reimbursed market access, even at the cost of short-term revenue decline, is a common and necessary step for medical device companies seeking sustainable long-term growth and broad adoption in a reimbursement-driven healthcare system.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from raised revenue guidance, reduced operating expense guidance, improved net loss, and strategic leadership appointments aimed at driving long-term growth and profitability. Board restructuring and executive changes could signal a more focused and efficient management structure.
• Employees: Impacted by the reduction in force announced in August 2025, which incurred $2.8 million in restructuring costs and is expected to yield $12.0 million in annualized savings. Promotions of internal candidates (Bauerlein, Rodberg) may boost morale for other employees.
• Customers (Eyecare Providers): Positive impact from expanded reimbursement coverage for TearCare and OMNI, making these innovative technologies more accessible to patients. Continued clinical evidence generation supports product efficacy.
• Patients: Positive impact from expanded access to interventional treatments for glaucoma and dry eye due to improved reimbursement coverage and ongoing clinical validation of product effectiveness.
• Creditors: Stable long-term debt of $40.0 million and a healthy cash balance of $92.4 million suggest continued financial stability, despite cash usage in the quarter.

Next Steps

• Continue to execute on opportunities in interventional dry eye and glaucoma segments.
• Maintain momentum in both segments while driving strong gross margins and disciplined expense management.
• Leverage the strengthened executive team to execute strategic plans and support profitable growth.
• Expand OMNI utilization by certifying new surgeons, gaining share in combination cataract, and developing the standalone pseudophakic MIGS segment.
• Generate additional clinical evidence for OMNI.
• Enhance coverage and equitable reimbursement for TearCare.
• Generate eyecare provider engagement and pursue coverage and equitable reimbursement for TearCare.
• Grow the commercial team and expand adoption and usage of TearCare.
• Generate additional clinical evidence to drive procedural DED intervention.
• File the A&R Bauerlein Agreement and Rodberg Agreement as exhibits to the Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

The company has demonstrated strong operational execution, evidenced by raised revenue guidance and reduced operating expense guidance, indicating a path towards improved financial health. Key executive promotions and board restructuring suggest a focused leadership team. Crucially, significant reimbursement milestones for both TearCare and OMNI are transformational, expanding market access and paving the way for sustained long-term growth in large, underserved eyecare markets. While Dry Eye revenue saw a strategic decline, this is a necessary step for long-term market penetration. The combination of financial discipline, strategic market access wins, and a strengthened leadership team makes this an attractive investment opportunity.

Keywords

Eyecare technology, Glaucoma, Dry eye disease, MIGS, OMNI Surgical System, TearCare System, Financial results, Medical devices, Reimbursement, Corporate governance, Executive appointments, SGHT, Ophthalmology